/LENZ

LENZ Stock - LENZ Therapeutics, Inc.

Q: What is the analyst price target for LENZ?

Analyst price target information is not currently available for LENZ.

Q: What is LENZ's market cap?

Market capitalization information is not currently available for LENZ.

Healthcare|Biotechnology|NASDAQ

$16.60+6.62%

+$1.03 (+6.62%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+237.3%upside

Target: $55.99

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for LENZ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.49

52W High$50.40

52W Low$14.43

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	$15.00M	N/A	N/A
Gross Profit	$-58,000	N/A	$15.00M	$-734,000	$-121,000
Gross Margin	N/A	N/A	100.0%	N/A	N/A
Operating Income	$-58,610,000	$-72,429,000	$-10,483,000	$-60,443,000	$-13,500,000
Net Income	$-49,769,000	$-69,968,000	$-10,811,000	$-70,760,000	$-68,373,000
Net Margin	N/A	N/A	-72.1%	N/A	N/A
EPS	$-2.34	$-15.30	$-12.89	$-8.54	$-8.24

Company Overview

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Visit Website

Earnings History & Surprises

LENZ

Beat Rate

60%

Last 15 quarters

Avg Surprise

-30.0%

EPS vs Estimate

Beats / Misses

9/6

Last 12 quarters

Latest EPS

$-0.59

Q4 2025

EPS Surprise History

Q1 24

-207.7%

$-0.40vs$-0.13

Q2 24

-320.2%

$-3.53vs$-0.84

Q3 24

+18.4%

$-0.40vs$-0.49

Q4 24

+19.1%

$-0.38vs$-0.47

Q1 25

-9.5%

$-0.46vs$-0.42

Q2 25

+3.6%

$-0.53vs$-0.55

Q3 25

+8.6%

$-0.53vs$-0.58

Q4 25

+11.9%

$-0.59vs$-0.67

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 18, 2026	$-0.97	—	—	—
Q4 2025	Nov 5, 2025	$-0.67	$-0.59	+11.9%	✓ BEAT
Q3 2025	Jul 30, 2025	$-0.58	$-0.53	+8.6%	✓ BEAT
Q2 2025	May 7, 2025	$-0.55	$-0.53	+3.6%	✓ BEAT
Q1 2025	Mar 19, 2025	$-0.42	$-0.46	-9.5%	✗ MISS
Q4 2024	Nov 6, 2024	$-0.47	$-0.38	+19.1%	✓ BEAT
Q3 2024	Aug 14, 2024	$-0.49	$-0.40	+18.4%	✓ BEAT
Q2 2024	May 8, 2024	$-0.84	$-3.53	-320.2%	✗ MISS
Q1 2024	Feb 27, 2024	$-0.13	$-0.40	-207.7%	✗ MISS
Q4 2023	Nov 13, 2023	$-0.25	$-0.19	+24.0%	✓ BEAT
Q2 2023	Jun 29, 2023	$-6.79	$-6.82	-0.5%	✗ MISS
Q1 2023	Mar 30, 2023	$-2.41	$-3.00	-24.5%	✗ MISS
Q4 2022	Dec 30, 2022	$-3.45	$-3.09	+10.5%	✓ BEAT
Q3 2022	Sep 29, 2022	$-3.11	$-3.13	-0.6%	✗ MISS
Q2 2022	Jun 29, 2022	$-3.44	$-3.42	+0.6%	✓ BEAT
Q1 2022	Mar 30, 2022	—	$-3.39	—	—
Q4 2021	Dec 30, 2021	$-2.73	$-2.28	+16.3%	✓ BEAT
Q3 2021	Sep 29, 2021	—	$-1.76	—	—
Q2 2021	Jun 29, 2021	—	$-2.19	—	—
Q1 2021	Mar 31, 2021	—	$-2.38	—	—

Frequently Asked Questions about LENZ

What is LENZ's current stock price?

LENZ Therapeutics, Inc. (LENZ) is currently trading at $16.60 per share. The stock has moved +6.62% today.

What is the analyst price target for LENZ?

The average analyst price target for LENZ is $56.00, based on 1 analyst.

What sector is LENZ Therapeutics, Inc. in?

LENZ Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is LENZ's market cap?

LENZ Therapeutics, Inc. has a market capitalization of $0.46 billion, making it a small-cap company.

Does LENZ pay dividends?

No, LENZ Therapeutics, Inc. does not currently pay a dividend to shareholders.